Downtime, Dollars & Data: Avoiding the Hidden Costs of Flow

Episode #32 of The Conversational Flow explores several significant developments shaping the flow cytometry and biopharmaceutical industries, including advances in antibody drug conjugates (ADCs), questions surrounding circadian timing in cancer treatment, and major life sciences acquisitions. Our hosts, Brian and Adam, discuss how improvements in ADC linker technology and broader first-line applications are helping revive interest in this therapeutic platform, while also examining why a recently retracted study on treatment timing still highlights an important avenue for future research. The conversation then shifts to industry trends, including large-scale mergers and acquisitions and their implications for drug development and laboratory suppliers. The featured discussion focuses on a published survey of flow cytometry core facilities, examining instrument maintenance, staffing, uptime, and best practices.

“The Conversational Flow” an official podcast of KCAS Bio, and focuses on the more niche topic of Flow Cytometry and its role within the greater pharmaceutical, biopharmaceutical and bioanalytical industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Flow Cytometry experts as they chat over coffee and discuss what they’ve learned about the world of Flow Cytometry the past couple of weeks. “The Conversational Flow” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.